Tharimmune Inc.(THAR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

THAR Tharimmune Inc.

Pre-Market Trading 04-09 07:10:20 EDT

1.08

-0.09

-7.69%

High1.19	Low1.05	Vol44.57K
Open1.16	D1 Closing1.17	Amplitude11.67%
Mkt Cap2.28M	Tradable Cap2.24M	Total Shares2.11M
T/O49.65K	T/O Rate2.15%	Tradable Shares2.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"THAR","market":"US","secType":"STK","nameCN":"Tharimmune Inc.","latestPrice":1.08,"timestamp":1744142400000,"preClose":1.17,"halted":0,"volume":44574,"delay":0,"floatShares":2077500,"shares":2108753,"eps":-11.954124,"marketStatus":"Pre-Market Trading","change":-0.09,"latestTime":"04-09 07:10:20 EDT","open":1.155,"high":1.1865,"low":1.05,"amount":49651.687326600004,"amplitude":0.116667,"askPrice":1.13,"askSize":100,"bidPrice":0.8585,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-11.954124,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744205400000},"marketStatusCode":1,"adr":0,"listingDate":1641963600000,"exchange":"NASDAQ","adjPreClose":1.08,"postHourTrading":{"tag":"盘后","latestPrice":1.16,"preClose":1.08,"latestTime":"18:27 EDT","volume":7003,"amount":7260.93,"timestamp":1744151245773},"volumeRatio":0.3031222121549433},"requestUrl":"/m/hq/s/THAR","defaultTab":"news","newsList":[{"id":"2525040436","title":"Tharimmune Reports Preclinical Data for Dual-Target Biologics","url":"https://stock-news.laohu8.com/highlight/detail?id=2525040436","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525040436?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 22:59","pubTimestamp":1744037964,"startTime":"0","endTime":"0","summary":"Tharimmune  reported Monday preclinical data from its expanded pipeline featuring dual-target biologics HS1940 and HS3215, which it says was \"positive.\"HS1940 is designed to bind to both programmed death-1, or PD-1, and vascular endothelial growth factor, or VEGF, potentially improving treatment outcomes for various cancers. HS3215 targets human epidermal growth factor receptors 2 and 3, or HER2 and HER3, key proteins involved in cancer growth. HS1940 and HS3215 were developed using Tharimmune's antibody engineering platform, EpiClick Technology, the company said.The company also said it aims to further improve the binding characteristics of HS1940 and present more data at future conferences, with plans to begin investigational new drug, or IND-enabling studies in 2025. Tharimmune also said it is conducting preclinical studies on HS3215 and plans to advance it into clinical trials after IND-enabling studies.Shares of Tharimmune were down nearly 7% in recent trading.Price: 1.10, Change:","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2525045439","title":"Tharimmune announces preclinical data from expanded pipeline with HS1940","url":"https://stock-news.laohu8.com/highlight/detail?id=2525045439","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525045439?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 21:20","pubTimestamp":1744032038,"startTime":"0","endTime":"0","summary":"Tharimmune (THAR) announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to bot...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tharimmune-announces-preclinical-data-from-expanded-pipeline-with-hs1940?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tharimmune-announces-preclinical-data-from-expanded-pipeline-with-hs1940?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2525048827","title":"BRIEF-Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2525048827","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525048827?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 20:39","pubTimestamp":1744029563,"startTime":"0","endTime":"0","summary":"BRIEF-Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) TechnologyApril 7 (Reuters) - Tharimmune Inc THAR.O:TH","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL059:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","THAR"],"gpt_icon":1},{"id":"2525223017","title":"Fw: [Ext] News: Tharimmune Announces Positive Data With Novel Biparatopic Pd-1/Vegf and Multispecific Her2/Her3 Biologics Leveraging Proprietary Epiclick(Tm) Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2525223017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525223017?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 20:15","pubTimestamp":1744028154,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL059:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2525045971","title":"Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2525045971","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525045971?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc.  , a clinical-stage biotechnology company focused on immunology and inflammation, today announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Programmed Death-1  and Vascular Endothelial Growth Factor , and HS3215, a dual-target biologic binding to Human Epidermal Growth Factors 2  and 3  receptors. Using its proprietary EpiClick Technology, a versatile multispecific antibody engineering platform, HS1940 and HS3215 represent a key expansion of Tharimmune's product pipeline and underscores the Company's commitment to addressing unmet needs.HS1940 is designed as a biparatopic  biologic, simultaneously engaging the PD-1 pathway and inhibiting angiogenesis. By using multiple, previously undruggable epitopes on PD-1, and blocking VEGF-mediated tumor vascularization, HS1940 may broaden treatment options and improve outcomes across multiple types of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-positive-data-novel-120000722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TM","LU1169590202.USD","BK4588","BK4099","BK4604","03160","THAR","PBC","BK4555","BK4585","PD","LU1169589451.USD","BK4023"],"gpt_icon":0},{"id":"2523992996","title":"Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure","url":"https://stock-news.laohu8.com/highlight/detail?id=2523992996","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523992996?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 23:18","pubTimestamp":1743434326,"startTime":"0","endTime":"0","summary":"Tharimmune (THAR) said Monday the US Food and Drug Administration has advised that no additional clinical trials are required to support a new drug application for TH104 as a prophylaxis against opioi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2523464949","title":"Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure","url":"https://stock-news.laohu8.com/highlight/detail?id=2523464949","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523464949?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"-Received positive feedback on New Drug Application submission via the 505 pathway. -Company leveraging existing human pharmacokinetic data with TH104. -Advancing CMC plan to meet requirements of a New Drug Application. \"This feedback from the FDA marks a significant milestone for Tharimmune and for individuals who may face the threat of ultrapotent opioid exposure,\" said Randy Milby, CEO. \"We believe that a rapidly biodegradable buccal film offers prophylactic protection against respiratory distress in such situations represents a crucial advancement. The 505 pathway along with leveraging the established safety and efficacy of the active ingredient, allows us to expedite the development and potential availability of this important product without the need for further clinical trials.\". Specifically, by inputting detailed data from previous human studies conducted by Tharimmune that characterized the PK of the active ingredient via buccal administration as well as existing published da","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-positive-fda-feedback-120000749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKVL7J92.USD","PBC","PK","BK4139","LU0882574139.USD","LU1363072403.SGD","BK4218","LU0170899867.USD","IE00BZ1G4Q59.USD","BK4135","IE00BHPRN162.USD","LU0971096721.USD","THAR","CMC","BK4181","LU0267386448.USD","CNS","IE00B1BXHZ80.USD","BK4006","LU0149725797.USD"],"gpt_icon":0},{"id":"2521723978","title":"Tharimmune announce preclinical TH023 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521723978","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521723978?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:36","pubTimestamp":1742819768,"startTime":"0","endTime":"0","summary":"Tharimmune (THAR) announced preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized pla...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tharimmune-announce-preclinical-th023-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tharimmune-announce-preclinical-th023-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2521747478","title":"Tharimmune: Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-Alpha","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747478","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747478?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:07","pubTimestamp":1742818063,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q716D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2521725882","title":"Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha","url":"https://stock-news.laohu8.com/highlight/detail?id=2521725882","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521725882?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc.  , a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha  inhibitor, in serum with concentrations detected being significantly higher than the standard serum trough concentration needed for antibody efficacy in immunology indications via injection . These findings represent a significant step towards developing a more convenient and potentially patient-preferred alternative to currently available infliximab treatments, which are administered via intravenous infusion or subcutaneous injection.The Company announced last year through a partnership with Intract Pharma, an exclusive license to INT-023 (now","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-positive-results-novel-120000890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["THAR","PBC","PK","BK4218","BK4181","IBD","BK4139"],"gpt_icon":0},{"id":"2516678211","title":"Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2516678211","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516678211?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:00","pubTimestamp":1741089600,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc.  , a clinical-stage biotechnology company focused on immunology and inflammation, today announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Programmed Death-1  and Vascular Endothelial Growth Factor  receptors. Using its proprietary EpiClick Technology, a versatile multispecific antibody engineering platform, HS1940 represents a key expansion of Tharimmune's product pipeline and underscores the Company's commitment to addressing unmet needs.The Company has generated positive target engagement data showing that the biparatopic format expands therapeutic versatility compared with monospecific antibodies, which are limited to targeting a single epitope on a single receptor. As illustrated, the biparatopic antibody constructs effectively achieve target engagement on both PD-1 and VEGF. By engaging two distinct","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-positive-target-engagement-120000409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","THAR","LU1169590202.USD","LU1169589451.USD","PD","BK4023","PBC"],"gpt_icon":0},{"id":"2514359902","title":"BRIEF-Tharimmune Says Thomas Hess Resigns As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2514359902","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514359902?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 06:34","pubTimestamp":1740695649,"startTime":"0","endTime":"0","summary":"BRIEF-Tharimmune Says Thomas Hess Resigns As CFO Feb 27  - Tharimmune Inc THAR.O:THARIMMUNE INC - THOMAS HESS RESIGNS AS CFO OF THARIMMUNE EFFECTIVE MARCH 26, 2025THARIMMUNE INC - APPOINTS DON KIM AS CFO EFFECTIVE MARCH 27, 2025Source text: [ID:n0001493152-25-008538]Further company coverage: THAR.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI2BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2514355540","title":"Tharimmune Inc - Thomas Hess Resigns as CFO of Tharimmune Effective March 26, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2514355540","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514355540?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 05:50","pubTimestamp":1740693038,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI2BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2506377826","title":"Tharimmune to Present at the Microcap Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2506377826","media":"ACCESS Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506377826?lang=en_us&edition=full_marsco","pubTime":"2025-01-27 21:30","pubTimestamp":1737984600,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc.  , a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.Event: The Microcap Conference 2025Location: Studio 4, Borgata Hotel Casino & SpaDate: Thursday January 30, 2025Time: 10:00 AM Eastern Time. Investors interested in meeting with management can register for the conference here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-present-microcap-conference-2025-133000334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBC","BK4139","THAR"],"gpt_icon":0},{"id":"2492484245","title":"Tharimmune files to sell 1.44M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2492484245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492484245?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 05:20","pubTimestamp":1734643235,"startTime":"0","endTime":"0","summary":"16:19 EST Tharimmune (THAR) files to sell 1.44M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tharimmune-files-to-sell-1-44m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tharimmune-files-to-sell-1-44m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2491169153","title":"Tharimmune to Initiate Phase 2 Study of TH104 for Reducing Itch in Cholangitis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2491169153","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491169153?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 22:06","pubTimestamp":1734357960,"startTime":"0","endTime":"0","summary":"Tharimmune  said Monday it plans to initiate a phase 2 study that will evaluate TH104 in reducing itch in patients with primary biliary cholangitis, a rare, chronic liver disease.The clinical trial, expected to begin in 2025, follows results from a phase 1 study and recent regulatory feedback from the European Medicines Agency and the US Food and Drug Administration, the biotechnology company said.Preliminary results from the trial, which has a planned enrollment of 40 patients, are expected in late 2025, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2491934726","title":"Tharimmune: Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2491934726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491934726?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 21:04","pubTimestamp":1734354267,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH08B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2491932016","title":"Tharimmune: Plan to Report Preliminary Results From Phase 2 Trial in Late 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2491932016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491932016?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 21:04","pubTimestamp":1734354267,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH08B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2491691929","title":"Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2491691929","media":"ACCESSWIRE","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491691929?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 21:00","pubTimestamp":1734354000,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc.  , a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus  associated with primary biliary cholangitis , a rare and chronic liver disease, and also provided a corporate update. The launch of this clinical trial, expected in 2025, follows favorable results from Tharimmune's Phase 1 study with TH104, recent regulatory feedback from the European Medicines Agency  and the U.S. Food and Drug Administration , as well as progress on manufacturing clinical study supply.Throughout 2024 Tharimmune achieved significant milestones across three key areas. These accomplishments reflect progress in advancing innovative therapies in inflammation and immunology, with a focus on improving patient outcomes in areas of high unmet need.Validation and batches of manufa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-phase-2-study-130000978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBC","THAR","BK4139"],"gpt_icon":0},{"id":"2489071261","title":"BRIEF-Tharimmune Inc Announces $2.02 Million Private Placement To Advance Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2489071261","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489071261?lang=en_us&edition=full_marsco","pubTime":"2024-12-07 05:39","pubTimestamp":1733521175,"startTime":"0","endTime":"0","summary":"Dec 6 (Reuters) - Tharimmune Inc   :   * THARIMMUNE INC: ANNOUNCES $2.02 MILLION PRIVATE PLACEMENT TO ADVANCE DEVELOPMENT PROGRAMSSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tharimmune.com","stockEarnings":[{"period":"1week","weight":-0.1562},{"period":"1month","weight":-0.2895},{"period":"3month","weight":-0.5023},{"period":"6month","weight":-0.4698},{"period":"1year","weight":-0.8362},{"period":"ytd","weight":-0.468}],"compareEarnings":[{"period":"1week","weight":-0.115},{"period":"1month","weight":-0.1379},{"period":"3month","weight":-0.1578},{"period":"6month","weight":-0.1383},{"period":"1year","weight":-0.0429},{"period":"ytd","weight":-0.1529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.636153},{"month":2,"riseRate":0,"avgChangeRate":-0.256211},{"month":3,"riseRate":0.25,"avgChangeRate":-0.086128},{"month":4,"riseRate":0,"avgChangeRate":-0.25725},{"month":5,"riseRate":0,"avgChangeRate":-0.204074},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.115478},{"month":7,"riseRate":0.333333,"avgChangeRate":0.127203},{"month":8,"riseRate":0,"avgChangeRate":-0.21679},{"month":9,"riseRate":0,"avgChangeRate":-0.142448},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.128388},{"month":11,"riseRate":0,"avgChangeRate":-0.45022},{"month":12,"riseRate":0,"avgChangeRate":-0.141486}],"exchange":"NASDAQ","name":"Tharimmune Inc.","nameEN":"Tharimmune Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.2","shortVersion":"4.32.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tharimmune Inc.(THAR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tharimmune Inc.(THAR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tharimmune Inc.,THAR,Tharimmune Inc.股票,Tharimmune Inc.股票老虎,Tharimmune Inc.股票老虎国际,Tharimmune Inc.行情,Tharimmune Inc.股票行情,Tharimmune Inc.股价,Tharimmune Inc.股市,Tharimmune Inc.股票价格,Tharimmune Inc.股票交易,Tharimmune Inc.股票购买,Tharimmune Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tharimmune Inc.(THAR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tharimmune Inc.(THAR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction